Mesoblast - ADR Share Price Today

Mesoblast highlights Ryoncil use in pediatric GvHD webinar

Mesoblast hosted a webinar featuring Dr. Susan Prockop from Harvard Medical School. Discussion centered on Ryoncil as a first-line treatment after steroids for pediatric aGvHD. Ryoncil is the first FDA-approved mesenchymal stromal cell therapy for SR-aGvHD. Company holds over 1,000 granted patents or applications protecting products through 2044.

Mesoblast secures FDA approval for new Ryoncil potency assay

FDA approves TIBA assay for Ryoncil release and stability monitoring. New assay detects potency shifts during manufacturing changes. TIBA works with IL-2Rα inhibition and CAP assays for quality control. Ryoncil remains only MSC product approved for SR-aGvHD patients.

Mesoblast FY26 revenue rises to $120M; net loss narrows 44%

Mesoblast reported FY26 revenue of $120.3M, up from $17.2M prior year. Net loss narrowed 44% to $57.5M from $102.1M last year. Gross profit excluding amortization reached $109.7M vs $16.0M previously. Cash burn in H2 fell sharply to $13.4M from $50M in prior period. Company secured new $125M credit facility replacing older debt.

Mesoblast to host FY26 financial results webcast on August 26

Mesoblast to discuss FY26 financial results ending June 30, 2026. Webcast scheduled for August 26, 2026, at 6:30 pm EDT. Company develops allogeneic cellular medicines for inflammatory diseases. Ryoncil is the first FDA-approved MSC therapy for pediatric SR-aGvHD. IP portfolio includes over 1,000 patents with protection through 2044.

Mesoblast completes Phase 3 trial dosing for chronic back pain therapy

Mesoblast Limited completed patient treatment in its pivotal Phase 3 trial for rexlemestrocel-L, a cellular therapy for chronic low back pain. The study treated 350 patients, exceeding the initial target of 300 due to high investigator demand. Results confirming durable pain reduction at 12 months are expected in mid-2027.

Mesoblast posts $36M Ryoncil revenue in Q4, holds $103M cash

Mesoblast Limited delivered strong Q4 results with $36M in Ryoncil revenue, bringing full-year totals to $115M. By drawing down $50M to clear debt, the firm secured a $103M cash position, fueling ongoing clinical trials for broader indications in graft-versus-host disease and muscular dystrophy.